Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

• US 9,498,476 B2
• Filed: 08/31/2015
• Issued: 11/22/2016
• Est. Priority Date: 06/04/2008
• Status: Active Grant

• Current Assignee: Albany Molecular Research Incorporated
• Original Assignee: Albany Molecular Research Incorporated
• Inventors: Qiu, Jun, Gao, Qi, Liu, Shuang, Hu, Min, Yang, Yuh-Lin Allen, Isherwood, Matthew, Amin, Rasidul
• Primary Examiner(s): CHONG, YONG SOO
• Application Number:
  US14/841,024
• Publication Number:
  US 20150366864A1
• Time in Patent Office: 449 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/435 having six-membered rings with one nitrogen as the only ring hetero atom
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/501 not condensed and containing further heterocyclic rings
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond

Abstract

The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Claims

1. A method of treating depression in a mammal in need thereof comprising administering to the mammal a therapeutically-effective amount of Form N-1 of

2. The method of claim 1 wherein the mammal is a human.